What Are the Risks Associated with Accelerated Approval?
The primary risk is that treatments may be approved based on less comprehensive data, which might not fully capture long-term safety and efficacy. This can lead to scenarios where benefits are overestimated, and risks are underestimated. Post-marketing surveillance becomes essential to monitor the real-world performance of these treatments.
